Purchase Description.pdf
PDF 148 KB Posted
- Attached to
- Custom Antibody-conjugated drugs (ADC) services
- Solicitation number
- 75N95024Q00376
About this file
This document is a Purchase Description for a federal contract opportunity to provide Custom Antibody-conjugated drugs (ADC) services. The objective is to generate two custom ADCs (antibody vc-MMAE conjugates) within 10 weeks of initiation, using antibodies supplied by the vendor. The minimum quantity required per ADC is 50 mg, delivered in a physiological buffer at a defined concentration with low aggregation.
The related federal contract opportunity is Solicitation Number 75N95024Q00376, issued by the Department of Health and Human Services' National Institutes of Health, National Institute on Drug Abuse. This is a small business set-aside requirement for Custom Antibody-conjugated drugs (ADC) services. The Government anticipates awarding a firm-fixed price purchase order with a 30-day delivery after receipt of order. Responses are due by July 29, 2024 at 12:00 pm EST and must include evidence of technical capability, past performance, price, and compliance with administrative requirements.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Purchase Description_Revised.pdf | ||
| FAR 52.204-24 (Nov 2021).pdf | ||
| FAR 52.204-26 (Oct 2020).pdf | ||
| FAR 52.212-5 (Feb 2024).pdf | ||
| Invoicing Instructions.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Version 11-30-2016-1 FAR Part 11—Describing Agency Needs
PURCHASE DESCRIPTION
1. Statement of Need and Purpose: Custom Antibody-conjugated drugs (ADC) services
2. Background Information and Objective:
Antibody-conjugated drugs (ADCs) are a targeted therapeutic strategy used to treat diseases of aging by combining the specificity of antibodies with the potency of cytotoxic drugs. The antibodies in ADCs are designed to recognize and bind to specific antigens that are overexpressed on the surface of aging or diseased cells, such as in certain cancers or senescent cells. Once bound, the ADC is internalized by the cell, where the cytotoxic drug is released, selectively killing the diseased cells while minimizing damage to healthy cells. This targeted approach enhances treatment efficacy and reduces side effects, addressing age-related diseases with greater precision and safety.
The application of custom antibody-directed cytotoxicity holds immense promise in addressing the need to target and eliminate senescent cells in vivo within the realm of vascular senescence research. Senescent cells accumulate in aging tissues and contribute to age-related vascular pathologies, necessitating innovative therapeutic strategies for their removal. Custom antibodies engineered to specifically target surface markers or antigens expressed by senescent cells can be conjugated to cytotoxic effector molecules, such as toxins or immune cell-recruiting agents. This approach enables precise recognition and destruction of senescent cells while sparing healthy cells, thus mitigating potential off-target effects. By harnessing the power of antibody-directed cytotoxicity, researchers can develop targeted therapies to selectively eradicate senescent cells in vascular tissues, offering promising avenues for combating age-related vascular diseases and promoting healthy aging.
3. Generic Name of Product: Custom ADC Services for two ADCs
4. Purchase Description:
Generation of 2 custom antibody-drug conjugates
5. Salient characteristics:
• Generation of 2 custom ADCs (antibody vc-MMAE conjugate). Delivery within 10 weeks of generation initiation, barring any unforeseen circumstances.
• Antibody for conjugation supplied by the vendor.
• Mimimum quantity of 50 mg per antibody-conjugate.
Version 11-30-2016-1 FAR Part 11—Describing Agency Needs
• Antibodies should be delivered in physiological buffer with a defined concentration.
• Aggregation should be <10% and unconjugated antibody <10%.
• ADC developed for research use only, with the capability of being injected into mice for research purposes as well as in vitro usage.
6. Quantity: Quantity of 2 custom ADCs (minimum of 50 mg each)
7. Delivery Date: 30 days after receipt of award
8. Option(s): N/A
File details come from the government source that posted it. Updated .